|
Early treatment initiation in lower-risk myelodysplastic syndromes produces an earlier and higher rate of transfusion independence
|
Aug 2017
|
Leuk Res
|
myelodysplastic syndromes (MDS)
|
|
A combination of thalidomide and arsenic trioxide is effective and well tolerated in patients with myelodysplastic syndromes
|
Jan 2012
|
Leuk Res
|
myelodysplastic syndromes (MDS)
|
|
Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine
|
Mar 2014
|
Leuk Res
|
myelodysplastic syndromes (MDS)
|
|
Relation between chelation and clinical outcomes in lower-risk patients with myelodysplastic syndromes: Registry analysis at 5 years
|
Jan 2017
|
Leuk Res
|
myelodysplastic syndromes (MDS)
|
|
Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases
|
Mar 2015
|
Leuk Res
|
myelodysplastic syndromes (MDS)
|
|
The role of T-cells in the pathogenesis of myelodysplastic syndromes: Passengers and drivers
|
Dec 2012
|
Leuk Res
|
myelodysplastic syndromes (MDS)
|
|
Seroreactivity to LGL leukemia-specific epitopes in aplastic anemia, myelodysplastic syndrome and paroxysmal nocturnal hemoglobinuria: results of a bone marrow failure consortium study.
|
Mar 2012
|
Leuk Res
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Variations in erythropoiesis-stimulating agent administration in transfusion-dependent myelodysplastic syndromes impact response
|
Mar 2015
|
Leuk Res
|
myelodysplastic syndromes (MDS)
|
|
Low efficacy and high mortality associated with clofarabine treatment of relapsed/refractory acute myeloid leukemia and myelodysplastic syndromes
|
Feb 2015
|
Leuk Res
|
myelodysplastic syndromes (MDS)
|
|
Historical perspectives on myelodysplastic syndromes
|
Aug 2012
|
Leuk Res
|
myelodysplastic syndromes (MDS)
|
